208 related articles for article (PubMed ID: 7881414)
1. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene.
Mulligan LM; Eng C; Attié T; Lyonnet S; Marsh DJ; Hyland VJ; Robinson BG; Frilling A; Verellen-Dumoulin C; Safar A
Hum Mol Genet; 1994 Dec; 3(12):2163-7. PubMed ID: 7881414
[TBL] [Abstract][Full Text] [Related]
2. RET mutations in exons 13 and 14 of FMTC patients.
Bolino A; Schuffenecker I; Luo Y; Seri M; Silengo M; Tocco T; Chabrier G; Houdent C; Murat A; Schlumberger M
Oncogene; 1995 Jun; 10(12):2415-9. PubMed ID: 7784092
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
4. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families.
Marsh DJ; Robinson BG; Andrew S; Richardson AL; Pojer R; Schnitzler M; Mulligan LM; Hyland VJ
Genomics; 1994 Sep; 23(2):477-9. PubMed ID: 7835899
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
6. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
[TBL] [Abstract][Full Text] [Related]
7. The RET proto-oncogene and cancer.
Donis-Keller H
J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
[TBL] [Abstract][Full Text] [Related]
8. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
9. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.
Hofstra RM; Fattoruso O; Quadro L; Wu Y; Libroia A; Verga U; Colantuoni V; Buys CH
J Clin Endocrinol Metab; 1997 Dec; 82(12):4176-8. PubMed ID: 9398735
[TBL] [Abstract][Full Text] [Related]
10. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
12. A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease.
Dvoráková S; Dvoráková K; Malíková M; Skába R; Vlcek P; Bendlová B
J Pediatr Surg; 2005 Jun; 40(6):e1-6. PubMed ID: 15991157
[TBL] [Abstract][Full Text] [Related]
13. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Mulligan LM; Eng C; Healey CS; Clayton D; Kwok JB; Gardner E; Ponder MA; Frilling A; Jackson CE; Lehnert H
Nat Genet; 1994 Jan; 6(1):70-4. PubMed ID: 7907913
[TBL] [Abstract][Full Text] [Related]
14. RET proto-oncogene mutations in French MEN 2A and FMTC families.
Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
[TBL] [Abstract][Full Text] [Related]
15. Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis.
Peacock ML; Borst MJ; Sweet JD; Decker RA
Hum Mutat; 1996; 7(2):100-4. PubMed ID: 8829625
[TBL] [Abstract][Full Text] [Related]
16. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
[TBL] [Abstract][Full Text] [Related]
17. Familial associations in medullary thyroid carcinoma with Hirschsprung disease: the role of the RET-C620 "Janus" genetic variation.
Moore SW; Zaahl M
J Pediatr Surg; 2010 Feb; 45(2):393-6. PubMed ID: 20152359
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
19. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.
Nishikawa M; Murakumo Y; Imai T; Kawai K; Nagaya M; Funahashi H; Nakao A; Takahashi M
Eur J Hum Genet; 2003 May; 11(5):364-8. PubMed ID: 12734540
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.
Mulligan LM; Marsh DJ; Robinson BG; Schuffenecker I; Zedenius J; Lips CJ; Gagel RF; Takai SI; Noll WW; Fink M
J Intern Med; 1995 Oct; 238(4):343-6. PubMed ID: 7595170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
